Withdrawal of valproic acid during pregnancy in women with epilepsy
| Autor: | H. I. Navumava, P. N. Vlasov, A. I. Prusakova, A. A. Usoltseva, N. A. Shnayder, D. V. Dmitrenko |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Неврология, нейропсихиатрия, психосоматика, Vol 15, Iss 2, Pp 27-33 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2074-2711 2310-1342 |
| DOI: | 10.14412/2074-2711-2023-2-27-33 |
| Popis: | Objective: to analyze the course of epilepsy in women after withdrawal of valproic acid (VA) during pregnancy. Material and methods. The study was conducted in the Center of paroxysmal conditions of Vitebsk Regional Clinical Diagnostic Center. The study included 58 women with epilepsy who gave birth in 2018–2020; a prospective analysis was also done using the Russian Register of Pregnancy and Epilepsy (RRPE) data. The study group included 112 women with epilepsy who were taking VA at the time of conception. In 16.1% of cases (n=18 out of 112) VA was discontinued in the first trimester (withdrawal group), in 83.9% of cases (n=94) VA therapy was continued. We analyzed the frequency of epileptic seizures depending on the use of VA during pregnancy for each trimester and for the entire pregnancy as a whole. Results. According to the Vitebsk Regional Clinical Diagnostic Center, 32 out of 58 (55.2%) patients took VA, all of them had generalized tonicclonic seizures in the structure of epileptic seizures. Seven of 32 patients (21.8%) received VA at a dose of 700 mg/day in the first trimester and throughout gestation. There were no statistically significant differences in the frequency of tonic-clonic and other types of epileptic seizures during pregnancy in patients who canceled VA and continued therapy, according to RRPE. Conclusion. Further prospective and controlled studies with large sample sizes are needed to determine the most effective and safe strategy for VA withdrawal. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|